These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27041524)

  • 1. Effects of Synbiotics Supplementation in Lean Patients with Nonalcoholic Fatty Liver Disease: Study Protocol of a Pilot Randomized Double-blind Clinical Trial.
    Mofidi F; Yari Z; Poustchi H; Merat S; Nourinayyer B; Malekzadeh R; Hekmatdoost A
    Arch Iran Med; 2016 Apr; 19(4):282-4. PubMed ID: 27041524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.
    Eslamparast T; Poustchi H; Zamani F; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Am J Clin Nutr; 2014 Mar; 99(3):535-42. PubMed ID: 24401715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Childs CE; Del Fabbro S; Bilson J; Moyses HE; Clough GF; Sethi JK; Patel J; Wright M; Breen DJ; Peebles C; Darekar A; Aspinall R; Fowell AJ; Dowman JK; Nobili V; Targher G; Delzenne NM; Bindels LB; Calder PC; Byrne CD
    Gastroenterology; 2020 May; 158(6):1597-1610.e7. PubMed ID: 31987796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.
    Sayari S; Neishaboori H; Jameshorani M
    Clin Mol Hepatol; 2018 Sep; 24(3):331-338. PubMed ID: 29890569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Prebiotic and Synbiotic Supplementation on Inflammatory Markers and Anthropometric Indices After Roux-en-Y Gastric Bypass: A Randomized, Triple-blind, Placebo-controlled Pilot Study.
    Fernandes R; Beserra BT; Mocellin MC; Kuntz MG; da Rosa JS; de Miranda RC; Schreiber CS; Fröde TS; Nunes EA; Trindade EB
    J Clin Gastroenterol; 2016 Mar; 50(3):208-17. PubMed ID: 25909598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach.
    Sangouni AA; Ghavamzadeh S
    Diabetes Metab Syndr; 2019; 13(5):2917-2922. PubMed ID: 31425956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial.
    Abhari K; Saadati S; Yari Z; Hosseini H; Hedayati M; Abhari S; Alavian SM; Hekmatdoost A
    Clin Nutr ESPEN; 2020 Oct; 39():53-60. PubMed ID: 32859329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study.
    Eslamparast T; Zamani F; Hekmatdoost A; Sharafkhah M; Eghtesad S; Malekzadeh R; Poustchi H
    Br J Nutr; 2014 Aug; 112(3):438-45. PubMed ID: 24848793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial.
    Mantri A; Köhlmoos A; Schelski DS; Seel W; Stoffel-Wagner B; Krawitz P; Stehle P; Holst JJ; Weber B; Koban L; Plassmann H; Simon MC
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of synbiotic supplementation on lactating mothers' energy intake and BMI, and infants' growth.
    Ostadrahimi A; Nikniaz L; Mahdavi R; Hejazi MA; Nikniaz Z
    Int J Food Sci Nutr; 2013 Sep; 64(6):711-4. PubMed ID: 23480276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synbiotics could not reduce the scoring of childhood atopic dermatitis (SCORAD): a randomized double blind placebo-controlled trial.
    Shafiei A; Moin M; Pourpak Z; Gharagozlou M; Aghamohammadi A; Sajedi V; soheili H; Sotoodeh S; Movahedi M
    Iran J Allergy Asthma Immunol; 2011 Mar; 10(1):21-8. PubMed ID: 21358011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
    Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
    Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
    Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R;
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
    Foster T; Budoff MJ; Saab S; Ahmadi N; Gordon C; Guerci AD
    Am J Gastroenterol; 2011 Jan; 106(1):71-7. PubMed ID: 20842109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.